Akebia Therapeutics, Inc. - Common Stock (AKBA)

Akebia (AKBA) Q4 2025 Earnings Call Transcript

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

The company said that the sale extends its cash runway into the second half of 2027.

Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding Vafseo's label.

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.